Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

Trial Profile

A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oplunofusp (Primary)
  • Indications Betacoronavirus infections; COVID 2019 infections; Enterovirus infections; Hypoxaemia; Influenza virus infections; Metapneumovirus infections; Parainfluenza virus infections
  • Focus Therapeutic Use
  • Acronyms STOP-Flu
  • Sponsors Ansun Biopharma
  • Most Recent Events

    • 16 Aug 2023 Results published in the Clinical Infectious Diseases
    • 08 Jul 2020 Planned initiation date changed from 1 Apr 2020 to 1 Jul 2020.
    • 01 Apr 2020 Planned initiation date changed from 1 Mar 2020 to 1 Apr 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top